SOUTHLAKE, Texas, June 25, 2018 –(BUSINESSWIRE)—HeartSciences, an innovative medical device company, is proud to announce its participation as an exhibitor at the upcoming 2018 International Congress on Electrocardiology (ICE), which will be held in Makuhari Messe, Chiba City, Japan, June 28-30, 2018.
HeartSciences: AI Improves Frontline Risk Stratification for Heart Diseases
Study demonstrates promising new capabilities for MyoVista® ECG device in detecting Abnormal Cardiac Function.
SOUTHLAKE, Texas, April 10, 2018 –(BUSINESSWIRE)—HeartSciences, a medical device company leading innovation in electrocardiography through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence announced today the results of a clinical study serially conducted at The Icahn School of Medicine, Mount Sinai Hospital, New York, NY and the West Virginia University (WVU) Heart and Vascular Institute, Morgantown, WV. The results were provided at onlineJACC.org, April 09, 2018 and will be published in the April 17, 2018 issue of Journal of the American College of Cardiology (JACC), a peer-reviewed journal in cardiovascular medicine.
Southlake, Texas – May 2, 2018 – HeartSciences, a U.S.-based medical device company that is leading innovation in the field of electrocardiology through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence, announced today that Peter W. Macfarlane has joined its board of clinical advisors.
Poster Title: Prediction of Cardiac Mechanical Relaxation Abnormalities from Surface ECG Wavelets Date: Sunday, March 11, 2018 at 3:45 p.m. Location: Orange County Convention Center | 9800 International Drive | Orlando, Florida 32819 USA | Hall A/B Poster: 1238-107 HeartSciences will participate in the Future Hub at ACC 2018. Future Hub is a multi-vendor educational […]
HeartSciences and MyoVista Cardiac Testing Device http://windsor.ctvnews.ca/video?clipId=1243217&binId=1.1143900&playlistPageNum=1
US-based medical device developer HeartSciences has launched its MyoVista high-sensitivity electrocardiograph (hsECG) Testing Device in Europe after receiving CE-Mark. MyoVista is intended to provide an effective, low-cost, front-line screening solution for cardiac disease in symptomatic as well as asymptomatic patients. Click here for full story
It’s no secret that both Apple and Google have their sights set on the healthcare market. Both have gradually become more involved with health-focused projects – the latter investing heavily in its life sciences division, Verily, and the former striking deals with health firms in its trademark covert fashion. Click here for the full story
European regulators gave HeartSciences CE mark approval for its MyoVista high sensitivity electrocardiograph testing device, a technology that uses Continuous Wavelet Transform to measure cardiac energy per heartbeat. The device, which is a combination of traditional 12-lead resting ECG tracings, ECG interpretive analysis and informatics, has also been launched by the company in Europe. Click […]
HeartSciences said today that its MyoVista high sensitivity electrocardiograph testing device won CE Mark and launched in Europe. The Westlake, Texas.-based company’s device measures the heart’s energy per heartbeat using Continuous Wavelet Transform, a type of advanced signal processing that provides doctors with a detailed visual description of a cardiac cycle’s energy distribution. Click here […]
European cardiologists may soon be able to detect the presence of heart disease more effectively in patients, thanks to a new advanced ECG tool. HeartSciences’ MyoVista high-sensitivity electrocardiograph (hsECG) Testing Device is now available for sale and distribution in markets across the European Union, following CE approval. Click here for the story
HeartSciences has started selling its MyoVista electrocardiograph (ECG) in Europe after picking up a CE mark. The device is designed to enable early detection of artery disease by visualizing energy distribution during cardiac cycles. Traditional ECGs detect and display the electrical signals the heart produces when it beats. The low cost and safety of the […]
HeartSciences is a medical device company with the mission to enable accurate, affordable screening for the early detection of heart disease. Our groundbreaking MyoVista® high-sensitivity ECG (hsECGTM) device advances the field of cardiac testing by filling the “diagnostic gap” in cardiac care and detecting cardiac dysfunction even in asymptomatic stages.
HeartSciences, a firm based outside of Dallas, Texas, is releasing in Europe its MyoVista high sensitivity electrocardiograph (hsECG) device that helps to screen patients for cardiac disease. It relies on a mathematical method known as continuous wavelet transform to process ECG data in a manner very different than conventional ECG. The company compares the way its MyoVista’s […]